Huron Elects Dr. L. Thomas Richards to Board of Directors

July 27, 2026

CHICAGO--(BUSINESS WIRE)--Jul. 27, 2026-- Global professional services firm Huron (NASDAQ: HURN) today announced Dr. L. Thomas Richards was elected to its Board of Directors, effective July 23, 2026. Dr. Richards is an experienced executive, senior advisor and board leader with deep expertise across life sciences and healthcare, capital markets, and corporate governance. He has a proven track record of helping organizations drive growth, unlock innovation, and accelerate value creation.

"We are pleased to welcome Tom to Huron's Board of Directors," said Hugh Sawyer, non-executive chairman of the Huron board. "Tom brings a unique combination of senior management, board leadership, and capital markets expertise across his roles as an investment banker, life sciences executive, physician, and board director. His global perspective, and expertise in evaluating and adopting new innovative technologies, and extensive governance experience in professional services will be a strong asset to our Board as we continue to advance Huron's growth strategy to create long-term value for our shareholders."

Dr. Richards most recently served as Chair of the Board of Directors of WittKieffer, an executive search and leadership advisory firm serving the healthcare, higher education, and life sciences sectors.

Throughout his career, Dr. Richards has led organizations at the intersection of healthcare, technology, and innovation. He previously served as Interim Chief Executive Officer of One Biomed, a molecular tools company, and Chief Executive Officer of TessArae, a molecular diagnostics company. He advises venture capital and private equity investors across the life sciences industry, with a focus on emerging technologies and innovation-driven growth and served as a Senior Advisor to Metis Genetics, One Biomed, and Nanomix. He also practiced academic medicine as an emergency physician and assistant professor at Stanford University and the University of California, San Francisco.

Earlier in his career, Dr. Richards was an investment banker in the mergers and acquisitions (M&A) groups of Lazard Frères, UBS, and SG Cowen.

Dr. Richards also has extensive governance experience serving on public, private, and nonprofit boards. He previously served on the board of directors of Cowen Group, Inc., a publicly traded financial services firm, and has served as a director of TessArae and One Biomed. He also currently serves on the board of two non-profit organizations, The World Telehealth Initiative and the Surfrider Foundation.

"I am honored to serve on Huron's Board of Directors," said Dr. L. Thomas Richards. "I look forward to partnering with my fellow directors and Huron's management team to build on the firm's strong momentum, advance its long-term strategy, and help create lasting value for its clients, people, and shareholders."

Dr. Richards received an M.D. from Harvard Medical School, an M.Phil. from the University of Sydney, and a B.A. from Yale University. He is a board-certified physician in Emergency Medicine.

The appointment of Dr. Richards to Huron's board reflects the firm's ongoing commitment to its periodic board refreshment process and brings the size of the board to 10 members.

ABOUT HURON

Huron is a global professional services firm that collaborates with organizations to help solve their most complex challenges and achieve their most ambitious goals. Working across the private and public sectors, we partner closely with clients to improve performance, accelerate transformation, and unlock new opportunities for growth.

Our clients choose us because of our deep industry and technical expertise and proven track record of turning sound strategies into action. By combining practical experience, innovative thinking, and advanced analytics and technology, Huron helps organizations translate today's ideas into tangible results and long-term value. Learn more at www.huronconsultinggroup.com.

Statements in this press release that are not historical in nature, including those concerning the company's current expectations about its future results, are "forward-looking" statements as defined in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by words such as "may," "should," "expects," "provides," "anticipates," "assumes," "can," "will," "meets," "could," "likely," "intends," "might," "predicts," "seeks," "would," "believes," "estimates," "plans," "positions," "continues," "goals," "guidance," or "outlook," or similar expressions. These forward-looking statements reflect the company's current expectations about future requirements and needs, results, levels of activity, performance, or achievements. Some of the factors that could cause actual results to differ materially from the forward-looking statements contained herein include, without limitation: failure to achieve expected utilization rates, billing rates, and the necessary number of revenue-generating professionals; our ability to realize the expected benefits and potential opportunities of artificial intelligence (AI); inability to expand or adjust our service offerings in response to market demands; our dependence on renewal of client-based services; dependence on new business and retention of current clients and qualified personnel; failure to maintain third-party provider relationships and strategic alliances; inability to license technology to and from third parties; the impairment of goodwill; various factors related to income and other taxes; difficulties in successfully integrating the businesses we acquire and achieving expected benefits from such acquisitions; risks relating to privacy, information security, and related laws and standards; and a general downturn or volatility in market conditions, including as a result of current global trade tensions and/or tariffs. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, including, among others, those described under "Item 1A. Risk Factors" in Huron's Annual Report on Form 10-K for the year ended December 31, 2025 that may cause actual results, levels of activity, performance or achievements to be materially different from any anticipated results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. The company disclaims any obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

MEDIA CONTACT
Allie Bovis
abovis@hcg.com

INVESTOR CONTACT
John D. Kelly
Investor@hcg.com

Source: Huron